Hansoh Biomedical R&d Company
Clinical trials sponsored by Hansoh Biomedical R&d Company, explained in plain language.
Research and development arm of a major Chinese pharmaceutical company.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New hope for tough esophageal cancer: HS-20093 enters final trial
Disease control Not yet recruitingThis Phase 3 trial tests a new drug called HS-20093 against standard chemotherapy in 494 people with advanced esophageal cancer that has worsened after initial treatment. The goal is to see if HS-20093 helps people live longer and controls the tumor better. Participants will rece…
Phase: PHASE3 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for lung cancer patients: combo therapy enters phase 3 trial
Disease control Not yet recruitingThis phase 3 study tests whether a new combination of drugs (HS-20093 plus adebrelimab) works better than the standard chemotherapy docetaxel for people with advanced or metastatic non-squamous non-small cell lung cancer that has already been treated. The trial plans to enroll 45…
Phase: PHASE3 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC